Sulfur requires specific protocols to encourage elimination
Several digital health companies similarly offer prescriptions for GLP-1s, and the manufacturers of those drugs, Eli Lilly and Novo Nordisk, are taking steps to make their treatments more accessible while also developing new ones for patients
Inhibition of SGLT-1 in the small intestine causes more glucose transport to the distal intestine and colon, resulting in greater fermentation of glucose to SCFAs by luminal bacteria and increased sustained release of GLP-1 in the distal intestine [174] (Fig
It may be considered for people who have already gone through the standard dosing schedule and may benefit from a higher dose under clinical supervision
Hinweis: Die in diesem Beitrag bereitgestellten Informationen dienen ausschlielich der allgemeinen Information und basieren auf aktuellen wissenschaftlichen Publikationen sowie ffentlich zugnglichen Forschungsdaten
doi: 10.1007/s11130-024-01254-y, PMID: [DOI] [PubMed] [Google Scholar] 32